SUNFLOWER(SZ:300111) Guan Cha Zhe Wang·2026-01-14 12:58Group 1 - The Zhejiang Securities Regulatory Bureau has initiated an investigation into Sunflower's restructuring plan due to misleading statements regarding the actual production capacity and business model of the restructuring target [1] - On January 14, Sunflower's stock fell by 10.01%, with a trading volume of 1.259 billion yuan and a turnover rate of 15.12%, bringing the total market value to 7.981 billion yuan [1] - In the first half of 2025, Sunflower reported an operating income of approximately 144 million yuan, a year-on-year decrease of 8.33%, and a net profit attributable to shareholders of approximately 1.1607 million yuan, down 35.68% year-on-year [3] Group 2 - Sunflower's main business focuses on the pharmaceutical sector, including the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [3] - The company plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical, which will become wholly-owned subsidiaries after the transaction [4] - The transaction is expected to constitute a major asset restructuring, expanding the company's business into the high-end semiconductor materials sector [4]